Related Experiment Video
Updated: May 28, 2026
07:43
Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model
Published on: August 5, 2021
Optogenetic therapy for retinitis pigmentosa.
V Busskamp1, S Picaud, J A Sahel
1Neural Circuit Laboratories, Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Gene Therapy
|October 14, 2011
Summary
Gene therapy using optogenetic tools can restore vision in retinitis pigmentosa (RP) models. This approach aims to create artificial photoreceptors to treat incurable blindness caused by RP.
Area of Science:
- Ophthalmology
- Neuroscience
- Genetics
Background:
- Retinitis pigmentosa (RP) is a group of inherited retinal diseases causing progressive vision loss.
- RP affects two million people globally, leading to incurable blindness.
- Current treatments for RP are limited.
Purpose of the Study:
- To review recent advancements in optogenetic engineering for RP treatment.
- To discuss the potential and limitations of using optogenetics to restore vision in RP patients.
- To evaluate the translational potential of optogenetic approaches using in vitro human retinal models.
Main Methods:
- Gene delivery of optogenetic tools (light-activated channels/pumps) to retinal cells.
- Restoration of photosensitivity in animal models of RP.
- In vitro studies using post-mortem human retinas to assess translational potential.
Main Results:
- Optogenetic tools successfully restored photosensitivity in animal models of RP.
- Restoration was observed at retinal, cortical, and behavioral levels.
- In vitro studies support the translational potential of this approach.
Conclusions:
- Optogenetic engineering shows promise for treating retinitis pigmentosa.
- Further research is needed to overcome limitations and optimize treatment strategies.
- This approach offers a potential pathway to restore vision in individuals with RP.
